| 2024-11-15 |
复牌提示：
2024-11-14 11:32:27 停牌，复牌日期 2024-11-14 11:37:27
|
| 2024-11-14 |
详情>>
内部人交易：
BIOTECH TARGET N V股份减少1279820.00股
|
| 2024-10-28 |
股东大会：
将于2024-11-26召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon a proposal to approve the dissolution of the Company in accordance with Section 275 of the Delaware General Corporation Law (the “Dissolution”) and the Plan of Liquidation and Dissolution (the “Plan of Dissolution”) which, if approved, will authorize the Board of Directors of the Company (the “Board of Directors”) to liquidate the Company in accordance with the terms thereof (the “Dissolution Proposal”);
2.To approve an adjournment of the special meeting, from time to time, if deemed necessary or advisable by the Board of Directors or a committee thereof, including to solicit additional proxies if there are not sufficient votes at the time of the special meeting to approve the Dissolution Proposal (the “Adjournment Proposal”);
3.To transact such other business that is properly presented by the Board of Directors at the special meeting and any adjournments or postponements thereof.
|
| 2024-08-14 |
详情>>
股本变动：
变动后总股本658.39万股
变动原因 ▼▲
- 原因：
- From March 31, 2024 to June 30, 2024
Issuance of common stock pursuant to private placement
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-1.26美元,归母净利润-752.5万美元,同比去年增长-32617.39%
|
| 2024-08-13 |
股东大会：
将于2024-09-27召开股东大会
会议内容 ▼▲
- 1.To elect one director to serve a three-year term expiring in 2027;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益0.11美元,归母净利润57.20万美元,同比去年增长-94.73%
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益-1.8美元,归母净利润-812.4万美元,同比去年增长91.24%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.99美元,归母净利润-417.6万美元,同比去年增长94.09%
|
| 2023-09-12 |
股东大会：
将于2023-10-27召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve three-year terms expiring in 2026;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending 2023;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2023-08-14 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益0.00美元,归母净利润-2.3万美元,同比去年增长99.95%
|
| 2023-07-18 |
股东大会：
将于2023-08-11召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our amended and restated certificate of incorporation, as amended, to effect a reverse stock split at a ratio of not less than 1-for-4 and not greater than 1-for-25, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders and with our Board of Directors able to elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion (the “Reverse Split”);
2.To approve the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Reverse Split proposal;
3.To transact any such other business that may properly come before the special meeting or any adjournment or postponement thereof.
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益0.19美元,归母净利润1084.50万美元,同比去年增长150.18%
|
| 2023-03-30 |
详情>>
业绩披露：
2022年年报每股收益-1.65美元,归母净利润-9271.8万美元,同比去年增长-11.7%
|
| 2022-11-10 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.25美元,归母净利润-7066.9万美元,同比去年增长2.88%
|
| 2022-08-12 |
详情>>
业绩披露：
2022年中报每股收益-0.82美元,归母净利润-4603.1万美元,同比去年增长-8.62%
|
| 2022-05-13 |
详情>>
业绩披露：
2022年一季报每股收益-0.38美元,归母净利润-2161.1万美元,同比去年增长19.30%
|
| 2022-04-27 |
股东大会：
将于2022-06-03召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve three-year terms expiring in 2025;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending 2022;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-03召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve three-year terms expiring in 2024;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending 2021;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2020-04-23 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve three-year terms expiring in 2023;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending 2020;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2019-04-26 |
股东大会：
将于2019-05-29召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve three-year terms expiring in 2022;
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending 2019;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
4.To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company’s named executive officers;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2018-04-30 |
股东大会：
将于2018-05-31召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve three-year terms expiring in 2021;
2.To approve the 2018 Equity Incentive Plan;
3.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending 2018;
4.To approve by an advisory vote the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2017-08-01 |
详情>>
拆分方案：
每11.0000合并分成1.0000股
|
| 2016-04-29 |
股东大会：
将于2016-06-24召开股东大会
会议内容 ▼▲
- 1. To elect the three nominees for Class III director named in the accompanying proxy statement to serve until the 2019 annual meeting of stockholders and until their successors have been duly elected and qualified.
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
3. To approve, on an advisory basis, the compensation of our Named Executive Officers as disclosed in the accompanying proxy statement.
4. To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2015-04-03 |
股东大会：
将于2015-05-26召开股东大会
会议内容 ▼▲
- 1. To elect the two nominees for Class II director named in the accompanying proxy statement to serve until the 2018 annual meeting of stockholders and until their successors have been duly elected and qualified.
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
3. To approve, on an advisory basis, the compensation of our Named Executive Officers as disclosed in the accompanying proxy statement.
4. To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|